» Articles » PMID: 30351060

Chitosan Immobilization on Bio-MOF Nanostructures: A Biocompatible PH-Responsive Nanocarrier for Doxorubicin Release on MCF-7 Cell Lines of Human Breast Cancer

Overview
Journal Inorg Chem
Specialty Chemistry
Date 2018 Oct 24
PMID 30351060
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

In this work, a bio-metal-organic framework (Bio-MOF) coated with a monodispersed layer of chitosan (CS; CS/Bio-MOF) was synthesized and applied as a pH-responsive and target-selective system for delivery of doxorubicin (DOX) in the treatment of breast cancer. The efficiency of the nanocarrier in loading and releasing DOX was assessed at different pH levels. To monitor the in vitro drug release behavior of the drug-loaded carrier, the carrier was immersed in a phosphate buffered saline solution (PBS, pH 7.4) at 37 °C. According to the observations, the nanocarrier presents a slow and continuous release profile as well as a noticeable drug loading capacity. In addition, the carrier demonstrates a pH-responsive and target-selective behavior by releasing a high amount of DOX at pH 6.8, which is indicative of tumor cells and inflamed tissues and releasing a substantially lower amount of DOX at higher pH values. In addition, the results indicated that pH is effective on DOX uptake by CS/Bio-MOF. A 3.6 mg amount of DOX was loaded into 10 mg of CS/Bio-MOF, resulting in a 21.7% removal at pH 7.4 and 93.0% at pH 6.8. The collapsing and swelling of the CS layers coated on the surface of the Bio-MOFs were found to be responsible for the observed pH dependence of DOX delivery. Moreover, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and the trypan blue test were performed on the MCF-7 (breast cancer) cell line in the presence of the CS/Bio-MOF carrier to confirm its biological compatibility. In addition, Annexin V staining was conducted to evaluate the cytotoxicity of the free and loaded DOX molecules. On the basis of the obtained optical microscopy, MTT assay, fluorescence microscopy, and dyeing results, the CS/Bio-MOF carrier greatly enhances cellular uptake of the drug by the MCF-7 cells and, therefore, apoptosis of the cells due to its biocompatibility and pH-responsive behavior.

Citing Articles

Metal-organic framework-based smart stimuli-responsive drug delivery systems for cancer therapy: advances, challenges, and future perspectives.

Guo Z, Xiao Y, Wu W, Zhe M, Yu P, Shakya S J Nanobiotechnology. 2025; 23(1):157.

PMID: 40022098 PMC: 11871784. DOI: 10.1186/s12951-025-03252-x.


Metal-organic frameworks in drug delivery: engineering versatile platforms for therapeutic applications.

Khafaga D, El-Morsy M, Faried H, Diab A, Shehab S, Saleh A RSC Adv. 2024; 14(41):30201-30229.

PMID: 39315019 PMC: 11418013. DOI: 10.1039/d4ra04441j.


Targeted biocompatible Zn-metal-organic framework nanocomposites for intelligent chemotherapy of breast cancer cells.

Fereydouni P, Al Mohaddesin A, Khaleghi S Sci Rep. 2024; 14(1):18311.

PMID: 39112669 PMC: 11306755. DOI: 10.1038/s41598-024-69457-6.


CLICK-FLISA Based on Metal-Organic Frameworks for Simultaneous Detection of Fumonisin B1 (FB1) and Zearalenone (ZEN) in Maize.

Zhang J, Zhu B, Zhang X, Peng Y, Li S, Han D Biosensors (Basel). 2024; 14(7).

PMID: 39056631 PMC: 11275017. DOI: 10.3390/bios14070355.


Microwave-Responsive Metal-Organic Frameworks (MOFs) for Enhanced In Vitro Controlled Release of Doxorubicin.

Fatima S, Sabouni R, Husseini G, Paul V, Gomaa H, Radha R Nanomaterials (Basel). 2024; 14(13).

PMID: 38998686 PMC: 11243425. DOI: 10.3390/nano14131081.